Cite
HARVARD Citation
Thomas, S. et al. (2020). Behcet's-like syndrome following pembrolizumab: An immune-related adverse event associated with programmed death receptor-1 inhibitor therapy. Journal of oncology pharmacy practice. pp. 995-999. [Online].